High-Mobility Group Box-1 Induces Decreased Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Retina

Mediators of Inflammation - Tập 2013 - Trang 1-11 - 2013
Ahmed M. Abu El‐Asrar1, Mohd Imtiaz Nawaz1, Mohammad Mairaj Siddiquei1, Abdullah S. Al-Kharashi1, Dustan Kangave1, Ghulam Mohammad1
1Department of Ophthalmology, College of Medicine, King Saud University, King Abdulaziz University Hospital, Old Airport Road, P.O. Box 245, Riyadh 11411, Saudi Arabia

Tóm tắt

To test the hypothesis that brain-derived neurotrophic factor-(BDNF-) mediated neuroprotection is reduced by high-mobility group box-1 (HMGB1) in diabetic retina, paired vitreous and serum samples from 46 proliferative diabetic retinopathy and 34 nondiabetic patients were assayed for BDNF, HMGB1, soluble receptor for advanced glycation end products (sRAGE), soluble intercellular adhesion molecule-1 (sICAM-1), monocyte chemoattractant protein-1 (MCP-1), and TBARS. We also examined retinas of diabetic and HMGB1 intravitreally injected rats. The effect of the HMGB1 inhibitor glycyrrhizin on diabetes-induced changes in retinal BDNF expressions was studied. Western blot, ELISA, and TBARS assays were used. BDNF was not detected in vitreous samples. BDNF levels were significantly lower in serum samples from diabetic patients compared with nondiabetics, whereas HMGB1, sRAGE, sICAM-1, and TBARS levels were significantly higher in diabetic serum samples. MCP-1 levels did not differ significantly. There was significant inverse correlation between serum levels of BDNF and HMGB1. Diabetes and intravitreal administration of HMGB1 induced significant upregulation of the expression of HMGB1, TBARS, and cleaved caspase-3, whereas the expression of BDNF and synaptophysin was significantly downregulated in rat retinas. Glycyrrhizin significantly attenuated diabetes-induced downregulation of BDNF. Our results suggest that HMGB1-induced downregulation of BDNF might be involved in pathogenesis of diabetic retinal neurodegeneration.

Từ khóa


Tài liệu tham khảo

10.2337/diabetes.53.9.2412

10.1016/S0278-5846(03)00023-X

10.1007/s00125-009-1655-6

10.1167/iovs.03-1392

10.1007/s11892-011-0198-7

10.1167/iovs.02-1089

10.1167/iovs.02-1332

10.1080/08977190410001723308

10.1007/s10456-008-9093-5

10.1046/j.1365-2796.2003.01204.x

10.1182/blood-2002-05-1300

10.1016/j.imbio.2009.11.001

2010, Current Drug Targets, 11, 1468, 10.2174/1389450111009011468

10.1080/07853890902806576

10.1523/JNEUROSCI.3732-10.2011

10.1096/fj.03-1476fje

10.1073/pnas.96.19.10836

10.1523/JNEUROSCI.3815-05.2006

10.1038/mt.2011.291

10.1016/j.nbd.2011.12.056

10.1167/iovs.11-7793

10.1155/2012/493043

2011, Molecular Vision, 17, 1829

2011, Molecular Vision, 17, 508

10.1016/j.chembiol.2007.03.007

10.1016/j.exer.2012.12.009

10.1016/0896-6273(91)90273-3

10.1263/jbb.105.395

10.1111/j.1463-1326.2006.00675.x

10.1007/s00125-006-0537-4

10.1016/j.clinbiochem.2008.03.003

10.1055/s-0031-1283161

10.1007/s00125-009-1263-5

10.1016/S0306-4522(01)00345-1

10.1111/j.1460-9568.2008.06322.x

10.2337/db07-1281

10.1373/clinchem.2005.051961

10.1007/s00125-006-0394-1

10.1007/s10238-008-0173-z

10.1016/S0168-8227(99)00083-2

10.1111/j.1464-5491.2011.03546.x

10.1096/fj.08-109033

10.2119/2006-00090.Nakamura

10.1016/j.bcp.2010.01.013

2009, Rheumatology, 48, 1190, 10.1093/rheumatology/kep199

10.1167/iovs.06-0495

10.1167/iovs.04-1409

10.2337/dc08-0558

10.1007/s005920200029

2000, Diabetes Care, 23, 234, 10.2337/diacare.23.2.234

10.1007/s592-001-8076-6

10.1046/j.1365-2796.2000.00705.x

1998, Hormone and Metabolic Research, 30, 146, 10.1055/s-2007-978854

10.2337/db09-0801

Thông tin
Thông tin xuất bản

Mediators of Inflammation

Tập 2013

1-11

Thông tin tác giả